Bigfoot Biomedical Raised $55m, Including Backing From Abbott

Bigfoot Biomedical said it raised $55m in a Series B financing, including a new undisclosed investment from partner Abbott Laboratories, bringing the start-up's total funding to $90m. The diabetes firm said it plans to use the money to fund clinical trials and marketing of its insulin pump and pen.

Diabetes

Milpitas, California-based Bigfoot Biomedical Inc. had already raised $37m in a Series B financing round in December 2017. The firm has now closed the round after raising another $18m, including funds from Abbott Laboratories Inc. as a first-time investor, along with other new and existing investors.

"We are excited to welcome Abbott to our list of investors," Jeffrey Brewer, president and CEO of Bigfoot Biomedical said. "Abbott's inclusion in our financing speaks to our two companies'...

More from Diabetic Care

More from Device Area